GlassScriptPhysician profile
Rachel C Bernstein
NPI 1831191568
$2,487.89
in general payments reported to CMS, 2019-2025
26 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $165 · 2021: $311 · 2022: $132 · 2023: $424 · 2024: $588 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,376.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $396.96 | 2021-2025 | |
| Abbvie INC. | $383.88 | 2019-2023 | Orilissa, Lo Loestrin Fe, Oriahnn |
| Bayer Healthcare Pharmaceuticals INC. | $249.00 | 2019-2025 | |
| Astellas Pharma US INC | $229.65 | 2022-2025 | Veozah |
| Millicent US INC | $156.65 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Novo Nordisk INC | $140.19 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $139.97 | 2019-2024 | |
| Hologic Sales and Service, LLC | $95.95 | 2023-2025 | Aptima, Myosure Tissue Removal Device, Thinprep 2000 Processor |
| Exeltis, USA INC. | $84.91 | 2020-2024 | Slynd |
| Therapeuticsmd, INC. | $81.09 | 2019-2021 | |
| Lupin INC. | $74.84 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $69.79 | 2023-2025 | Myfembree |
| Coopersurgical, INC. | $67.09 | 2019-2023 | Endosee |
| Agile Therapeutics, INC. | $50.75 | 2021 | |
| Amag Pharmaceuticals, INC. | $39.87 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $39.66 | 2024-2025 | Zurzuvae |
| Avion Pharmaceuticals | $26.75 | 2019-2023 | Balcoltra |
| Baxter Healthcare | $21.30 | 2025 | Perclot |
| Organon LLC | $20.49 | 2024 | |
| Duchesnay USA Incorporated | $20.48 | 2019 | |
| Evofem Biosciences, INC. | $18.30 | 2021 | |
| Roche Diagnostics Corporation | $17.83 | 2019 | |
| Mission Pharmacal Company | $16.09 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.00 | 2019 | |
| Meditrina | $15.78 | 2024 | |
| Lilly USA, LLC | $14.62 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.